PMID- 35274760
OWN - NLM
STAT- MEDLINE
DCOM- 20220525
LR  - 20220821
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 49
IP  - 6
DP  - 2022 Jun
TI  - MCTS1 promotes laryngeal squamous cell carcinoma cell growth via enhancing LARP7 
      stability.
PG  - 652-660
LID - 10.1111/1440-1681.13640 [doi]
AB  - MCTS1 Re-Initiation and Release Factor (MCTS1) has been characterised as an 
      oncoprotein in some cancers. In this study, we explored the expression of MCTS1 
      in laryngeal squamous cell carcinoma (LSCC) and its regulatory effects on the 
      proliferation and cell-cycle progression of tumour cells, as well as the 
      underlying mechanisms. The data from the Cancer Genome Atlas was used to analyse 
      MCTS1 expression and its correlation with survival outcomes in LSCC patients. 
      Subsequent in vitro cellular and molecular studies were performed based on 
      representative LSCC cell lines. Results showed that the upregulation of MCTS1 in 
      LSCC is linked to poor progression-free survival (PFS) and disease-specific 
      survival (DSS). In TU177 and AMC-HN-8 cells, MCTS1 exerted positive regulations 
      on cell viability, colony formation, cell cycle progression, and the expression 
      of CDK1, CDK2, cyclin A2, and cyclin B1. Co-IP assay confirmed mutual interaction 
      between MCTS1 and LARP7, mainly in the cytoplasm. Cycloheximide (CHX) chase and 
      co-IP assay of ubiquitination showed that MCTS1 could increase LARP7 protein 
      half-life and reduce its poly-ubiquitination. LARP7 overexpression enhanced the 
      viability and colony formation of LSCC cells and also elevated the expression of 
      CDK1, CDK2, cyclin A2, and cyclin B1. In addition, its overexpression partly 
      reversed the negative influence of MCTS1 knockdown. In summary, this study 
      confirmed that the expression of MCTS1 might be an indicator of unfavourable 
      prognosis for patients with LSCC. Mechanically, it promotes LSCC cell viability 
      and proliferation via interacting with LARP7 and reducing its 
      proteasomal-mediated degradation.
CI  - (c) 2022 John Wiley & Sons Australia, Ltd.
FAU - Yang, Mengsheng
AU  - Yang M
AUID- ORCID: 0000-0002-8701-0820
AD  - Otorhinolaryngology - Head and Neck Surgery, Gansu Provincial Hospital, Lanzhou, 
      China.
FAU - Ma, Binjuan
AU  - Ma B
AD  - Otorhinolaryngology - Head and Neck Surgery, Gansu Provincial Hospital, Lanzhou, 
      China.
FAU - Liu, Xiangyi
AU  - Liu X
AD  - Otorhinolaryngology - Head and Neck Surgery, Affiliated Hospital of Gansu 
      University of Traditional Chinese Medicine, Lanzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220328
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cyclin A2)
RN  - 0 (Cyclin B1)
RN  - 0 (Larp7 protein, human)
RN  - 0 (MCTS1 protein, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Ribonucleoproteins)
SB  - IM
MH  - Cell Cycle Proteins/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Cyclin A2/genetics/metabolism
MH  - Cyclin B1/genetics/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - *Head and Neck Neoplasms
MH  - Humans
MH  - *Laryngeal Neoplasms/genetics/pathology
MH  - *MicroRNAs/genetics
MH  - Oncogene Proteins/metabolism
MH  - Ribonucleoproteins/genetics/metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
OTO - NOTNLM
OT  - LARP7
OT  - LSCC
OT  - MCTS1
OT  - proliferation
OT  - ubiquitin
EDAT- 2022/03/12 06:00
MHDA- 2022/05/26 06:00
CRDT- 2022/03/11 08:47
PHST- 2022/02/21 00:00 [revised]
PHST- 2021/10/31 00:00 [received]
PHST- 2022/02/27 00:00 [accepted]
PHST- 2022/03/12 06:00 [pubmed]
PHST- 2022/05/26 06:00 [medline]
PHST- 2022/03/11 08:47 [entrez]
AID - 10.1111/1440-1681.13640 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2022 Jun;49(6):652-660. doi: 10.1111/1440-1681.13640. 
      Epub 2022 Mar 28.